Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease.
- Author:
Joo Hyun LIM
1
;
Sang Gyun KIM
;
Ji Hyun SONG
;
Jae Jin HWANG
;
Dong Ho LEE
;
Jae Pil HAN
;
Su Jin HONG
;
Ji Hyun KIM
;
Seong Woo JEON
;
Gwang Ha KIM
;
Ki Nam SHIM
;
Woon Geon SHIN
;
Tae Ho KIM
;
Sun Moon KIM
;
Il Kwon CHUNG
;
Hyun Soo KIM
;
Heung Up KIM
;
Joongyub LEE
;
Jae Gyu KIM
Author Information
- Publication Type:Original Article
- Keywords: Levofloxacin; KW -; Helicobacter pylori; Third-line eradication
- MeSH: Amoxicillin; Clarithromycin; Compliance; Follow-Up Studies; Helicobacter pylori*; Helicobacter*; Humans; Levofloxacin; Peptic Ulcer*; Ulcer
- From:Gut and Liver 2017;11(2):226-231
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. METHODS: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. RESULTS: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655). CONCLUSIONS: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
